ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

AXNX Axonics Inc

67.28
0.17 (0.25%)
04 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Axonics Inc NASDAQ:AXNX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.17 0.25% 67.28 65.22 67.50 67.39 66.81 67.38 398,176 01:00:00

Axonics® to Participate in Piper Sandler Virtual Healthcare Conference

08/11/2021 11:00am

Business Wire


Axonics (NASDAQ:AXNX)
Historical Stock Chart


From May 2021 to May 2024

Click Here for more Axonics Charts.

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to participate in the Piper Sandler Virtual Healthcare Conference on December 1, 2021.

In advance of the virtual conference, a pre-recorded fireside chat with Axonics senior management will be made available on Monday, November 22 at 10:00 AM Eastern Time. Interested parties may access the fireside chat by visiting the Axonics investor relations website.

About Axonics

Based in Irvine, Calif., Axonics is a global medical technology company that is developing and commercializing novel products for adults with bladder and bowel dysfunction. The company’s rechargeable sacral neuromodulation (SNM) system provides patients suffering from overactive bladder and/or fecal incontinence with long-lived, easy to use, safe, clinically effective therapy. In addition, Axonics’ best-in-class urethral bulking agent, Bulkamid®, provides safe and durable symptom relief to women with stress urinary incontinence (SUI).

Overactive bladder affects an estimated 87 million adults in the U.S. and Europe, with an additional 40 million adults estimated to suffer from fecal incontinence. SUI affects an estimated 20 million women in the U.S. alone. Axonics’ clinically proven products are offered at hundreds of medical centers across the U.S. and abroad. Reimbursement coverage is well established in the U.S. and is a covered service in most European countries. For more information, visit www.axonics.com.

Neil Bhalodkar Investor Relations 949-336-5293 ir@axonics.com

1 Year Axonics Chart

1 Year Axonics Chart

1 Month Axonics Chart

1 Month Axonics Chart

Your Recent History

Delayed Upgrade Clock